Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 27

1.

HPV16 E6 and E7 Upregulate Interferon-Induced Antiviral Response Genes ISG15 and IFIT1 in Human Trophoblast Cells.

Ambühl LMM, Villadsen AB, Baandrup U, Dybkær K, Sørensen S.

Pathogens. 2017 Sep 3;6(3). pii: E40. doi: 10.3390/pathogens6030040.

2.

Chronic total coronary occlusion: treatment results.

Kirk Christensen M, Freeman PF, Rasmussen JG, Villadsen AB, Raungaard B, Eggert Jensen S, Thuesen L.

Scand Cardiovasc J. 2017 Aug;51(4):197-201. doi: 10.1080/14017431.2017.1319575. Epub 2017 Apr 20.

PMID:
28425767
3.

Fractional Flow Reserve-Guided Complete Revascularization Improves the Prognosis in Patients With ST-Segment-Elevation Myocardial Infarction and Severe Nonculprit Disease: A DANAMI 3-PRIMULTI Substudy (Primary PCI in Patients With ST-Elevation Myocardial Infarction and Multivessel Disease: Treatment of Culprit Lesion Only or Complete Revascularization).

Lønborg J, Engstrøm T, Kelbæk H, Helqvist S, Kløvgaard L, Holmvang L, Pedersen F, Jørgensen E, Saunamäki K, Clemmensen P, De Backer O, Ravkilde J, Tilsted HH, Villadsen AB, Aarøe J, Jensen SE, Raungaard B, Køber L, Høfsten DE; DANAMI 3-PRIMULTI Investigators.

Circ Cardiovasc Interv. 2017 Apr;10(4). pii: e004460. doi: 10.1161/CIRCINTERVENTIONS.116.004460.

PMID:
28404623
4.

Comparison of Durable-Polymer Zotarolimus-Eluting and Biodegradable-Polymer Biolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease: 3-Year Clinical Outcomes in the Randomized SORT OUT VI Trial.

Raungaard B, Christiansen EH, Bøtker HE, Hansen HS, Ravkilde J, Thuesen L, Aarøe J, Villadsen AB, Terkelsen CJ, Krusell LR, Maeng M, Kristensen SD, Veien KT, Hansen KN, Junker A, Madsen M, Andersen SL, Jensen SE, Jensen LO; SORT OUT VI Investigators.

JACC Cardiovasc Interv. 2017 Feb 13;10(3):255-264. doi: 10.1016/j.jcin.2016.11.007. Epub 2017 Jan 18.

PMID:
28109874
5.

Randomized Comparison of a Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Stent With a Biodegradable Polymer Biolimus-Eluting Stent in Patients Treated With Percutaneous Coronary Intervention: The SORT OUT VII Trial.

Jensen LO, Thayssen P, Maeng M, Ravkilde J, Krusell LR, Raungaard B, Junker A, Terkelsen CJ, Veien KT, Villadsen AB, Kaltoft A, Tilsted HH, Hansen KN, Aaroe J, Kristensen SD, Hansen HS, Jensen SE, Madsen M, Bøtker HE, Berencsi K, Lassen JF, Christiansen EH.

Circ Cardiovasc Interv. 2016 Jul;9(7). pii: e003610. doi: 10.1161/CIRCINTERVENTIONS.115.003610.

6.

Deferred versus conventional stent implantation in patients with ST-segment elevation myocardial infarction (DANAMI 3-DEFER): an open-label, randomised controlled trial.

Kelbæk H, Høfsten DE, Køber L, Helqvist S, Kløvgaard L, Holmvang L, Jørgensen E, Pedersen F, Saunamäki K, De Backer O, Bang LE, Kofoed KF, Lønborg J, Ahtarovski K, Vejlstrup N, Bøtker HE, Terkelsen CJ, Christiansen EH, Ravkilde J, Tilsted HH, Villadsen AB, Aarøe J, Jensen SE, Raungaard B, Jensen LO, Clemmensen P, Grande P, Madsen JK, Torp-Pedersen C, Engstrøm T.

Lancet. 2016 May 28;387(10034):2199-206. doi: 10.1016/S0140-6736(16)30072-1. Epub 2016 Apr 3.

PMID:
27053444
7.

Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trial.

Engstrøm T, Kelbæk H, Helqvist S, Høfsten DE, Kløvgaard L, Holmvang L, Jørgensen E, Pedersen F, Saunamäki K, Clemmensen P, De Backer O, Ravkilde J, Tilsted HH, Villadsen AB, Aarøe J, Jensen SE, Raungaard B, Køber L; DANAMI-3—PRIMULTI Investigators.

Lancet. 2015 Aug 15;386(9994):665-71.

PMID:
26347918
8.

Zotarolimus-eluting durable-polymer-coated stent versus a biolimus-eluting biodegradable-polymer-coated stent in unselected patients undergoing percutaneous coronary intervention (SORT OUT VI): a randomised non-inferiority trial.

Raungaard B, Jensen LO, Tilsted HH, Christiansen EH, Maeng M, Terkelsen CJ, Krusell LR, Kaltoft A, Kristensen SD, Bøtker HE, Thuesen L, Aarøe J, Jensen SE, Villadsen AB, Thayssen P, Veien KT, Hansen KN, Junker A, Madsen M, Ravkilde J, Lassen JF; Scandinavian Organization for Randomized Trials with Clinical Outcome (SORT OUT).

Lancet. 2015 Apr 18;385(9977):1527-35. doi: 10.1016/S0140-6736(14)61794-3. Epub 2015 Jan 16. Erratum in: Lancet. 2015 Apr 18;385(9977):1510.

PMID:
25601789
9.

Differential clinical outcomes after 1 year versus 5 years in a randomised comparison of zotarolimus-eluting and sirolimus-eluting coronary stents (the SORT OUT III study): a multicentre, open-label, randomised superiority trial.

Maeng M, Tilsted HH, Jensen LO, Krusell LR, Kaltoft A, Kelbæk H, Villadsen AB, Ravkilde J, Hansen KN, Christiansen EH, Aarøe J, Jensen JS, Kristensen SD, Bøtker HE, Thuesen L, Madsen M, Thayssen P, Sørensen HT, Lassen JF.

Lancet. 2014 Jun 14;383(9934):2047-2056. doi: 10.1016/S0140-6736(14)60405-0. Epub 2014 Mar 14.

PMID:
24631162
10.

Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial.

Christiansen EH, Jensen LO, Thayssen P, Tilsted HH, Krusell LR, Hansen KN, Kaltoft A, Maeng M, Kristensen SD, Bøtker HE, Terkelsen CJ, Villadsen AB, Ravkilde J, Aarøe J, Madsen M, Thuesen L, Lassen JF; Scandinavian Organization for Randomized Trials with Clinical Outcome (SORT OUT) V investigators.

Lancet. 2013 Feb 23;381(9867):661-9. doi: 10.1016/S0140-6736(12)61962-X. Epub 2013 Jan 30. Erratum in: Lancet. 2013 Jul 27;382(9889):310. Noergaard, Bjarne Linde [corrected to Norgaard, Bjarne Linde].

PMID:
23374649
11.

3-Year clinical outcomes in the randomized SORT OUT III superiority trial comparing zotarolimus- and sirolimus-eluting coronary stents.

Maeng M, Tilsted HH, Jensen LO, Kaltoft A, Kelbæk H, Abildgaard U, Villadsen AB, Krusell LR, Ravkilde J, Hansen KN, Christiansen EH, Aarøe J, Jensen JS, Kristensen SD, Bøtker HE, Madsen M, Thayssen P, Sørensen HT, Thuesen L, Lassen JF.

JACC Cardiovasc Interv. 2012 Aug;5(8):812-8. doi: 10.1016/j.jcin.2012.04.008.

12.

Randomized comparison of everolimus-eluting and sirolimus-eluting stents in patients treated with percutaneous coronary intervention: the Scandinavian Organization for Randomized Trials with Clinical Outcome IV (SORT OUT IV).

Jensen LO, Thayssen P, Hansen HS, Christiansen EH, Tilsted HH, Krusell LR, Villadsen AB, Junker A, Hansen KN, Kaltoft A, Maeng M, Pedersen KE, Kristensen SD, Bøtker HE, Ravkilde J, Sanchez R, Aarøe J, Madsen M, Sørensen HT, Thuesen L, Lassen JF; Scandinavian Organization for Randomized Trials With Clinical Outcome IV (SORT OUT IV) Investigators.

Circulation. 2012 Mar 13;125(10):1246-55. doi: 10.1161/CIRCULATIONAHA.111.063644. Epub 2012 Feb 3. Erratum in: Circulation. 2013 Sep 3;128(10):e158. Noergaard, Bjarne Linde [corrected to Norgaard, Bjarne Linde].

13.

System delay and timing of intervention in acute myocardial infarction (from the Danish Acute Myocardial Infarction-2 [DANAMI-2] trial).

Nielsen PH, Terkelsen CJ, Nielsen TT, Thuesen L, Krusell LR, Thayssen P, Kelbaek H, Abildgaard U, Villadsen AB, Andersen HR, Maeng M; Danami-2 Investigators.

Am J Cardiol. 2011 Sep 15;108(6):776-81. doi: 10.1016/j.amjcard.2011.05.007. Epub 2011 Jul 15.

PMID:
21757183
14.

Outcome in high risk patients with unprotected left main coronary artery stenosis treated with percutaneous coronary intervention.

Jensen LO, Kaltoft A, Thayssen P, Tilsted HH, Christiansen EH, Mikkelsen KV, Maeng M, Hansen KN, Villadsen AB, Madsen M, Lassen JF, Pedersen KE, Thuesen L.

Catheter Cardiovasc Interv. 2010 Jan 1;75(1):101-8. doi: 10.1002/ccd.22205.

PMID:
19670299
15.

Timing, causes, and predictors of death after three years' follow-up in the Danish Multicenter Randomized Study of Fibrinolysis versus Primary Angioplasty in Acute Myocardial Infarction (DANAMI-2) trial.

Busk M, Maeng M, Kristensen SD, Thuesen L, Krusell LR, Mortensen LS, Steinmetz ER, Nielsen TT, Andersen HR; DANAMI-2 Investigators.

Am J Cardiol. 2009 Jul 15;104(2):210-5. doi: 10.1016/j.amjcard.2009.03.014. Epub 2009 May 18.

PMID:
19576349
16.

The Danish multicentre randomized study of fibrinolytic therapy vs. primary angioplasty in acute myocardial infarction (the DANAMI-2 trial): outcome after 3 years follow-up.

Busk M, Maeng M, Rasmussen K, Kelbaek H, Thayssen P, Abildgaard U, Vigholt E, Mortensen LS, Thuesen L, Kristensen SD, Nielsen TT, Andersen HR; DANAMI-2 Investigators.

Eur Heart J. 2008 May;29(10):1259-66. Epub 2007 Oct 23.

PMID:
17956874
17.
18.

[A year"s experience with primary percutaneous intervention as the standard treatment of patients with ST-elevation infarction in the County of North Jutland].

Rasmussen K, Ravkilde JL, Nielsen TV, Villadsen AB.

Ugeskr Laeger. 2005 Aug 15;167(33):3039-43. Danish.

PMID:
16109247
19.

A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction.

Andersen HR, Nielsen TT, Rasmussen K, Thuesen L, Kelbaek H, Thayssen P, Abildgaard U, Pedersen F, Madsen JK, Grande P, Villadsen AB, Krusell LR, Haghfelt T, Lomholt P, Husted SE, Vigholt E, Kjaergard HK, Mortensen LS; DANAMI-2 Investigators.

N Engl J Med. 2003 Aug 21;349(8):733-42.

20.

Percutaneous transluminal coronary angioplasty versus thrombolysis in acute myocardial infarction.

Hansen HH, Thuesen L, Rasmussen K, Andersen HR, Vesterlund T, Villadsen AB, Schroeder AP, Husted SE, Nielsen TT.

Scand Cardiovasc J. 2000 Aug;34(4):365-70.

PMID:
10983669

Supplemental Content

Loading ...
Support Center